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Background: Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4
(CTLA-4) that enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg).
In this study, we investigated whether inhibiting Treg activity with ipilimumab during ex vivo T cell expansion
could augment anti-CD3-driven T cell proliferation and enhance bispecific antibody (BiAb)-redirected antitumor
cytotoxicity of activated T cells (ATC).
Methods: PBMC from healthy individuals were stimulated with anti-CD3 monoclonal antibody with or without
ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi)
or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell
line or Burkitt’s lymphoma cell line (Daudi).
Results: In PBMC from healthy individuals, the addition of ipilimumab at the initiation of culture significantly
enhanced T cell proliferation (p = 0.0029). ATC grown in the presence of ipilimumab showed significantly
increased mean tumor-specific cytotoxicity at effector:target (E:T) ratio of 25:1 directed at COLO356/FG and Daudi
by 37.71% (p < 0.0004) and 27.5% (p < 0.0004), respectively, and increased the secretion of chemokines (CCL2,
CCL3, CCL4,CCL5, CXCL9, and granulocyte-macrophage colony stimulating factor(GM-CSF)) and cytokines (IFN-γ,
IL-2R, IL-12, and IL-13), while reducing IL-10 secretion.
Conclusions: Expansion of ATC in the presence of ipilimumab significantly improves not only the T cell proliferation
but it also enhances cytokine secretion and the specific cytotoxicity of T cells armed with bispecific antibodies.
Keywords: Ipilimumab, Cytotoxic T-lymphocyte antigen-4 (CTLA-4), Bispecific antibody, Pancreatic cancer,
Colorectal cancer, Burkitt’s lymphoma, Activated T cells, ImmunotherapyIntroduction
Efficacy of cancer immunotherapy using targeted T cells
has been limited by tumor-induced immunosuppression
or regulatory T cells (Tregs) that interfere with T cell ef-
fector functions resulting in failure to induce robust cellu-
lar and humoral antitumor responses. Since recent clinical
trial data show that cytotoxic T-lymphocyte antigen-4
(CTLA-4) positive Tregs are associated with reduced T
cell antitumor activities [1], we hypothesized that treat-
ment with anti-CTLA-4 monoclonal antibody (mAb)* Correspondence: luml@karmanos.org
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unless otherwise stated.during T cell expansion would augment the proliferative
and functional activities of activated T cells.
CTLA-4 is constitutively expressed on CD4+CD25high-
forkhead box P3+ (FOXP3+) Treg cells [2], transiently on
newly activated T cells and minimally or negative on naïve
T cells [3,4]. CTLA-4 is homologous to the co-stimulatory
receptor CD28 but competes for CD80 and CD86 binding
with much higher avidity [5-7] leading to suppression of T
cell activation [8,9]. CLTA-4 blockade studies have dem-
onstrated greater tumor regression in antibody-treated
mice [10-12]. Furthermore, Treg-depletion prior to block-
ing the CTLA-4 signaling pathway results in enhanced T
cell proliferation and tumor-specific cytotoxicity in vivo
[2,13] and in vitro [2].
Ipilimumab (Yervoy®, Bristol-Myers Squibb) is a hu-
man mAb antibody directed at CTLA-4 that inhibits thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tivation, therefore increasing the CD28 binding oppor-
tunity to the co-stimulatory factors for appropriate T cell
activation. In the FDA registration trial, ipilimumab sig-
nificantly improved the median overall survival from 6.4
months in the group that received gp100 alone to 10.0
or 10.1 months in the group that received ipilimumab
with or without gp100 (cancer vaccine comprises HLA-
A*0201–restricted peptides derived from the melanoso-
mal protein, glycoprotein 100 [gp100] [14]), respectively,
in patients with unresectable stage III and IV melanoma
[14]. However, 88.9% of the patients experienced derma-
tologic, gastrointestinal, or other immune-related ad-
verse events (irAEs) from ipilimumab of which 10-15%
were grade 3 or 4 that resulted in 2.1% drug-related
deaths [14]. Therefore, new approaches that provide the
antitumor effects of ipilimumab without the side effects
are needed. One approach to avoid irAEs would be by
adding ipilimumab at the initiation of T cell expansion
cultures to enhance the proliferation and cytotoxicity
mediated by BiAb-armed ATC. This study shows that
ipilimumab enhances T cell proliferation, tumor-specific
cytotoxicity mediated by BiAb, and cytokine secretion
without Treg-depletion prior to ATC expansion. These
results could be used to optimize antitumor activity in
immunotherapeutic approaches for patients with onco-
logical or hematological malignancies.
Materials and methods
Cell lines
The human Burkitt’s lymphoma cell line (Daudi) and hu-
man pancreatic cancer cell line (COLO356/FG) were main-
tained in RPMI-1640 or DMEM culture media (Lonza Inc.,
Allendale, NJ), respectively, supplemented with 10% fetal
bovine serum (FBS) (Valley Biomedical Inc., Winchester,
VA), 2 mM L-glutamine (Lonza Inc.), 50 IU/mL penicillin
and 50 μg/mL streptomycin (Lonza Inc.).
Generation of ATC
PBMC for ATC expansion were obtained from healthy
volunteers (KCI protocol 2007-012) and leukapheresis
samples from GI patients which were cryopreserved
prior to immunotherapy (KCI protocol 2011-025). Both
protocols were approved by the Wayne State University
Human Investigation Committee. T cells in the PBMC
were activated by 20 ng/mL of anti-CD3 monoclonal
antibody (OKT3, Ortho Biotech, Horsham, PA) and ex-
panded with 100 IU/mL of Interleukin-2 (IL-2) in
RPMI-1640 supplemented with 10% FBS, 2 mM L-
glutamine, 50 units/mL penicillin and 50 μg/mL strepto-
mycin (complete RPMI-1640) for 14 days at 37°C with
5% CO2. At the initiation of culture, ipilimumab (YER-
VOY® by Bristol-Myer Squibb, Princeton, NJ) was added
only once to the cultures at various concentrations (0,0.5, 5.0, and 50 μg/mL). Cultures were fed every 2 to 3
days and maintained at a concentration of 1x106 cells/
mL. IL-2 was added at every feeding at 100 IU/mL.
Production of bispecific antibodies and arming of ATC
Bispecific antibodies (BiAbs) were produced by chemical
heteroconjugation of OKT3 and Rituxan (a humanized
anti-CD20 IgG1, Genentech Inc., South San Francisco,
CA) or Erbitux (a humanized anti-epidermal growth fac-
tor receptor (EGFR) IgG1, ImClone LLC., Branchburg,
NJ) as described [15,16]. ATC were armed with anti-
OKT3 x anti-CD20 BiAb (CD20Bi) or anti-OKT3 x anti-
EGFR BiAb (EGFRBi) using a previously optimized
concentration (50 ng/106 ATC) [17].
Cytotoxicity/51Cr release assay
To target adherent cells, COLO356/FG cells were plated
in 96-well flat-bottom microtiter plates at 4x104 cells/
well and allowed to adhere overnight. The cells were la-
beled with 51Cr at 20 μCi/mL in the labeling media (50%
FBS in complete RPMI-1640) for 5 hours at 37°C, and
washed with complete RPMI-1640 to remove unincor-
porated isotope. For non-adherent cell targeting, Daudi
cells were labeled with 51Cr at 100 μCi/106 cells in a 15
mL conical tube for 4 hours at 37°C, washed with
complete RPMI-1640, and plated in 96-well round-
bottom microtiter plates at 1x104 cells/well. Effectors
(unarmed ATC and aATC) were then added to achieve
effector:target (E:T) ratios of 25:1 and 12.5:1. Co-
cultures were incubated for 4 hours (Daudi) or 18 hours
(COLO356/FG) and the supernatant was collected for li-
quid scintillation counting to quantitate the amount of
released 51Cr. Percent cytotoxicity was calculated as fol-
lows: (experimental cpm – spontaneous cpm)/(max-
imum cpm – spontaneous cpm) × 100 [15]. Means and
standard errors were calculated from four to six repli-
cates per sample.
T cell sub-population profiling
Changes in T cell sub-populations were quantitated by
flow cytometric analysis as described [18,19]. CD8-PE-
Cy5, CD16-PE, CD25-APC, CD45RA-FITC, CD45RO-PE,
CD56-APC, CD127-PE, and CD152-PE-Cy5 were pur-
chased from BD Biosciences (San Jose, CA). CD3-FITC
and CD4-APC were purchased from Miltenyi Biotec
(Auburn, CA).
Quantitation of released cytokines in co-cultures
ATC expanded with or without ipilimumab were armed
with EGFRBi and co-cultured with COLO356/FG at 10:1
E:T ratio. The amount of cytokines released by unarmed
ATC or aATC in the co-culture supernatant was quanti-
tated using 25-plex human cytokine Luminex Assay
(Invitrogen, Carlsbad, CA) in the Bio-Plex System (Bio-
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panel includes IL-1β, IL-1 receptor antagonist (IL-1Ra),
IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-13, IL-17,
tumor necrosis factor (TNF)-α, interferon (IFN)-α, IFN-
γ, granulocyte macrophage colony-stimulating factor
(GM-CSF), macrophage inhibitory protein (MIP)-1α
(CCL3), MIP-1β (CCL4), interferon inducible protein
(IP)-10, monokine induced by IFN-γ (MIG or CXCL9),
eotaxin, regulated on activation normal T cell expressed
and secreted (RANTES or CCL5), and monocyte
chemotactic protein (MCP)-1 (CCL2). Bio-Plex Manager
Software was used to calculate the cytokine concentra-
tions using a recombinant cytokines-derived standard
curve.
Statistical analysis
Quantitative data are presented as the means of at least
three or more independent experiments with standard er-
rors. Paired, two-tailed t-test and matched sample one-
way ANOVA were used to determine whether the data
were statistically significant.
Results
Ipilimumab affects T cell effector functions in dose
dependent manner
In order to determine the optimal in vitro concentration of
ipilimumab, concentrations equivalent to in vivo dosageFigure 1 Dose dependent enhancement of anti-tumor cytotoxicity of e
cell cytotoxicity was examined by adding ipilimumab at the initiation of ATC
from 0 to 50 μg/mL. ATC were harvested on day 14, armed with EGFRBi or CD
(left) or 4 hours with Daudi (right) for cytotoxicity assay. BiAb-mediated tumor s
a mean ± SE of 3 donors (COLO356/FG) or 4 donors (Daudi). The dose-depende
one-way ANOVA for COLO356/FG (*p < 0.05) and Daudi (**p < 0.05).(3mg/kg) [14] for an average body weight (~75-88kg)
[21] were tested in the ATC expansion culture by dose
titration. T cells in PBMC derived from three healthy
donors were activated by anti-CD3 mAb and expanded
with IL-2 for 10-14 days. The expansion cultures were
initiated with 0 (control), 0.5, 5.0, and 50 μg/mL of ipili-
mumab. ATC were harvested and armed with CD20Bi
or EGFRBi to target CD20 positive Burkitt’s lymphoma
cell line (Daudi) or EGFR positive pancreatic cancer cell
line (COLO356/FG), respectively. Cytotoxicity was mea-
sured by 51Cr release assay at effector:target (E:T) of
25:1. In both COLO356/FG and Daudi targeting,
tumor-specific cytotoxicity was significantly enhanced
(p < 0.05) in a dose dependent manner (Figure 1). The
highest T cell cytotoxicity was observed at 50 μg/mL of
ipilimumab with mean percent increases of 69.8% and
49.0% for EGFRBi and CD20Bi targeting, respectively.
Based on these results, a dose of 50 μg/mL was chosen
for all the subsequent experiments unless otherwise
indicated.
Enhanced cytotoxicity is sustained at lower E:T
In order to confirm the ability of ipilimumab to enhance
the specific cytotoxicity at lower E:T, 51Cr release assay
was repeated with healthy donors using the 50 μg/mL
dose of ipilimumab. Consistent with the dose titration
results, ipilimumab significantly enhanced the BiAb-xpanded ATC by ipilimumab. Effect of ipilimumab on BiAb-mediated T
expansion cultures from healthy donors at various concentrations ranging
20Bi, and co-cultured at 25:1 E:T ratio for 18 hours with COLO356/FG
pecific cytotoxicity was measured by 51Cr release assay. Each bar represents
nt effect of ipilimumab was statistically significant in matched sample,
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12.5:1 with both EGFRBi and CD20Bi, targeting
COLO356/FG and Daudi, respectively (Figure 2a and b).
The mean percent increases in the cytotoxicity were
37.7% (p = 0.0001) and 27.5% (p < 0.0004) against
COLO356/FG and Daudi. The enhanced cytotoxicity
was sustained at the lower E:T of 12.5:1, and EGFRBi
aATC had an even higher percent increase of 84.9%
(p < 0.0001) (Figure 2a).Figure 2 Enhanced BiAb mediated cytotoxicity in ipilimumab supplem
healthy donors were expanded with 0 (control) or 50 μg/mL of ipilimumab
specific cytotoxicity. EGFRBi armed ATC and COLO356/FG were co-cultured
difference in the specific cytotoxicity was measured by 51Cr release assay (l
normalized to the control group to calculate the percent increase (right). (
ratios of 25:1 (n = 11) and 12.5 (n = 8), and specific cytotoxicity was measur
ipilimumab group was normalized to the control group to calculate the pe
The bar within each box shows a median while + symbol represents a mea
t test was performed.Increased cytotoxicity by BiAb-armed T cells from
patients with gastrointestinal (GI) cancers in the presence
of ipilimumab
Since T cells obtained from cancer patients may be de-
fective in antitumor function due to an immunosuppres-
sive tumor microenvironment in vivo [22-27], we tested
whether ipilimumab could enhance cytotoxicity in T
cells from GI patients. T cells from cryopreserved leuka-
pheresis products of three patients with gastrointestinalented ATC of healthy donors. (a) T cells in PBMC derived from
, and ATC were harvested, armed and tested for BiAb-mediated tumor
for 18 hours at E:T ratios of 25:1 (n = 9) and 12.5:1 (n = 7), and
eft). Cytotoxicity of EGFRBi armed ATC in the ipilimumab group was
b) CD20Bi armed ATC and Daudi were co-cultured for 4 hours at E:T
ed by 51Cr release assay (left). Cytotoxicity of CD20Bi armed ATC in the
rcent increase (right). Each bar represents a mean ± SE for≥ 7 samples.
n for each data set. For each set of data, a paired two-tailed
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anti-CD3 mAb with or without ipilimumab and ex-
panded for 14 days with IL-2. Harvested ATC were
armed with EGFRBi and tested for cytotoxicity against
COLO356/FG at E:T of 25:1 and 12.5:1. Ipilimumab
clearly enhanced the EGFRBi-mediated tumor specific
cytotoxicity by ATC derived from GI patients (Figure 3,
left panel). The mean percent increases were 33.9%
(p = 0.017) and 32.7% (p = 0.021) at E:T of 25:1 and
12.5:1, respectively (Figure 3, right panel).Figure 3 Ipilimumab enhanced BiAb-mediated cytotoxicity of ATC de
cryopreserved PBMC of 3 patients with gastrointestinal cancer were expand
on day 14, armed with EGFRBi, and tested for the tumor specific cytotoxici
at E:T ratios of 25:1 and 12.5:1 E:T ratios. For each group, a paired two-tailed
the ipilimumab group was normalized to the control group to calculate th
tients. For each set of data, paired, two-tailed t test was performed. (lower)
anti-CD3 stimulation and expanded with IL-2 in the presence of 0 (control)
feeding to determine the T cell proliferation. The bars represent means forIpilimumab enhances proliferation of activated T cells
Both in vivo and in vitro studies have shown that block-
ing CTLA-4 signaling enhances T cell proliferation, and
in some cases, synergistic enhancement was observed
when Treg cells were depleted prior to T cell stimulation
[2,13]. We examined an effect of ipilimumab on the
proliferation of ATC from PBMC without physical Treg-
depletion. T cell proliferation was monitored by measur-
ing the cell concentrations each time the cultures were
fed. As shown in the lower panel of Figure 3, ATCrived from patients with gastrointestinal cancer. T cells in
ed with 0 (control) or 50 μg/mL ipilimumab, and ATC were harvested
ty (n = 3). (left): EGFRBi armed ATC and COLO356/FG were co-cultured
t test was performed. (right): Cytotoxicity of EGFRBi armed ATC in
e percent increase. Each bar represents a mean ± SE is shown for 3 pa-
: T cells in PBMC derived from healthy donors were activated with
or 50 μg/mL ipilimumab (n = 18). Cell counts were performed at each
each data set (paired two-tailed t test).
Figure 4 (See legend on next page.)
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Figure 4 Ipilimumab altered the T cell-subpopulation profile in expanded ATC. (a): ATC expanded with ipilimumab had a decreased CD4/8
ratio (n = 11) (left). The panel summarizes 11 experiments (n = 11); the bars in the boxes are medians while + symbols represent means. One
representative flow cytometry analysis is shown (right). (b): The proportion of CD4 and CD8 T cells were determined in the presence or absence
of ipilimumab. Control and ipilimumab groups in each of 11 experiments are connected with a trend line. (c): The expanded 8 ATC products
were analyzed by flow cytometry to show the change in the Treg population (CD3+CD4+CD25high/+CD127low/-). The bars in the boxes are
medians while + symbols represent means. (d): NKT cell population (CD3+CD56+) in the expanded ATC products is shown. Each bar represents a
mean with standard error of eight experiments (n = 8). Each bar represents a mean ± SE of 8 experiments, and paired, two-tailed t test
was performed.
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presence of ipilimumab.Ipilimumab decreases CD4/CD8 ratio and Treg population
in expanded ATC
Recent clinical studies demonstrated that patients who
receive ipilimumab exhibit increased proliferation of
both CD4 and CD8 T cells [28,29]. Based on the en-
hanced cytotoxicity and the increased proliferation of
ATC in our study, we hypothesized that ipilimumab may
enhance T cell cytotoxicity by preferentially promoting
CD8 T cell expansion. Expanded ATC were harvested
after 14 days of culture, and the changes in T cell sub-
populations were quantitated by flow cytometry. The
CD4/CD8 ratio was significantly decreased (p = 0.010)
in the presence of ipilimumab, indicating an increase
in CD8 population (Figure 4a). To clarify the changes
responsible for the decreased CD4/CD8 ratio, CD4
and CD8 T cell populations were separately quanti-
tated (Figure 4b). Proportion of CD4+ cells decreased
(p = 0.0011) while proportion of CD8+ cells increased
(p = 0.0430). There was no significant difference in
CD4CD8 double positive T cells (data not shown). Fur-
thermore, when the proportion of Treg cells between
control and ipilimumab-supplemented ATC preparations
were compared, there was a statistically significant re-
duction in the Treg population (n = 8, p = 0.0234) in the
ipilimumab group (Figure 4c).Secretion of immune activating chemokines and
cytokines were elevated by ipilimumab
ATC were expanded with ipilimumab at 0, 0.5, 5.0 and
50 μg/mL concentrations to determine whether ipilimu-
mab could alter the cytokine secretion levels in a dose
dependent manner. The harvested ATC were armed
with EGFRBi and co-cultured with COLO356/FG at 10:1
E:T for 24 hours and supernatants were harvested.
Among 25 different cytokines and chemokines in the
analysis panel, there was a pattern of dose dependent in-
crease in the secretion of chemokines CCL2, CCL3,
CCL4, CCL5, CXCL9, and GF-CSF (Figure 5a). Cytokine
analysis of the cultures also revealed that ATC expanded
in the presence of ipilimumab secreted increasedamount of IFN-γ, IL-2R, IL-12, and IL-13, whereas the
secretion of IL-10 was decreased (Figure 5b).
Discussion
Previously we have shown that T cells expanded from
the leukapheresis product or PBMC from the immuno-
suppressive environment of cancer patients can be stim-
ulated to improve their functions in vitro as well as
in vivo [30,31]. ATC armed with anti-CD3 x anti-tumor
associated antigen BiAbs exhibit high levels of specific
cytotoxicity against tumor cells expressing Her2/neu
[17,18,32], CD20 [15], GD2 [33], and EGFR [16,19] via
redirected non-MHC-restricted perforin/granzyme-
dependent killing. Furthermore, arming with BiAbs
creates artificial cytotoxic T lymphocytes wherein TCR
engagement via BiAb-bridge between the armed ATC
and the antigen on the tumor cells induces release of
significantly higher levels of IFN-γ, IL-2R, IL-12, CCL3,
CCL4 and CXCL9, compared to unarmed ATC used as
controls [19]. In this study, we demonstrated that the
addition of ipilimumab at the initiation of culture signifi-
cantly improves T cell proliferation, BiAb-mediated
tumor-specific cytotoxicity, and synthesis of inflamma-
tory chemokines and cytokines. Phenotypic analysis of T
cell subpopulations showed a decreased Tregs popula-
tion with a concomitant decrease in IL-10 secretion as
well as a reduced CD4/CD8 ratio in the ATC products
expanded in the presence of ipilimumab. The reduced
CD4/CD8 ratio may account for the increased specific
cytotoxicity. These data demonstrate that ipilimumab
can improve ATC proliferation and effector functions
while it diminishes immune suppressive Treg activity.
Enhanced T cell proliferation in the presence of ipili-
mumab may be due to the inhibition of the interaction
between pre-existing Treg cells and monocytes/dendritic
cells in PBMC that were indirectly activated upon anti-
CD3 stimulation of T cells. In addition, it is likely that
ipilimumab blocked the CTLA-4-mediated inhibitory
signaling in activated effector T cells as CTLA-4 expres-
sion is known to peak around 2 days after anti-CD3
stimulation [3,4]. However, it is not clear whether de-
creased CD4 percent population was due to a direct ef-
fect of ipilimumab on CD4 T cell proliferation or due to
an enhanced CD8 Tcell expansion induced by ipilimumab.
Figure 5 (See legend on next page.)
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Figure 5 The pattern of dose-dependent changes in cytokine secretion levels in ATC expanded with Ipilimumab. Anti-CD3 activated T cells in
PBMC derived from 3 healthy donors were cultured in the presence of 0 (control), 0.5, 5.0 and 50 μg/mL ipilimumab for 14 days. Harvested ATC were
armed with EGFRBi and co-cultured with COLO356/FG target cells at 10:1 E:T for 24 hours. The supernatants were collected and quantitated in the
multi-plex Luminex assay. (a): Shows changes in the secretion levels of CCL2, CCL3, CCL4, CCL5, CXCL9, and GM-CSF. (b): Shows changes in the
secretion levels of IL-2R, IFN-γ, IL-12, and IL-13. Each bar represents a mean ± SE of 3 healthy donors (n = 3).
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some healthy donors persisted during the ATC culture
period in both control and ipilimumab ATC prepara-
tions with no significant difference. NK cell activation is
a complex set of signal transduction pathways including
direct cell-cell signaling from APCs and humoralFigure 6 A schematic summary of our study results showing a pivota
cell activation. (a) CTLA-4 on the surface of Treg or early activated T cells
CD86 on antigen presenting cells. (b) Ipilimumab enhances proliferation of
the decreased CD4/CD8 ratio. The enhanced CD8+ T cell proliferation resul
Daudi and COLO356/FG models. The enhanced antitumor activity was con
secretion. Although there was no difference between control and ipilimum
activation may have contributed in the increased cytotoxicity and IFN-γ secsignaling via cytokines and chemokines [34]. Since the
ATC culture was fed with IL-2, which is a NK cell
stimulatory factor [34,35], and antigen-bound IgG is also
known to activate NK and NKT cells via Fcγ receptor
bindings [34], NKT cells may be activated by IL-2 and Fc
binding of ipilimumab bound to CTLA-4 on the surfacel role that ipilimumab may play in modulating T cell and NK/NKT
competes with CD28 in binding with co-stimulatory factors CD80 or
CD8+ T cells while proliferation of CD4+ T cells was reduced, hence
ted in the improved BiAb-mediated antitumor cytotoxicity in both
sistently observed in elevated secretion of IFN-γ and decreased IL-10
ab groups in NKT cell proliferation, ipilimumab-mediated NKT cell
retion.
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secretion of INF-γ and CTL activity. Additional studies
with purified NKT cells will be needed to address the ef-
fects of ipilimumab on NK and NKT cells.
The cytokine quantitation studies revealed that ipilimu-
mab enhances the secretion of various cytokines and che-
mokines in a dose-dependent manner. Dose dependent
(ipilimumab) increase in IFN-γ and IL-12 suggest gener-
ation of Th1 cytokines produced during armed ATC
mediated killing of target cells. These cytokines and che-
mokines may activate endogenous immune cells in vivo
[30,31]. However, the role of soluble IL-2R (sIL-2R) in cul-
ture supernatant is not clear. Both Tregs and activated T
cells can release IL-2R, and measurable levels of sIL-2R in
the blood have been shown to indicate sustained immune
activation [36]. On the other hand, sIL-2R also competes
for IL-2 binding on activated T cells, thereby inhibiting T
cell proliferation [36,37]. Increased release of sIL-2R has
also been shown to induce differentiation of CD4 T cells
into FOXP3+ Treg [38]. Since proliferation and activation
were both enhanced in the presence of ipilimumab, in-
creased levels of sIL-2R in this study are likely due to the
activation of T cells rather than its immune suppressive
activity.
Intriguingly, decreased levels of IL-10 suggest that ipili-
mumab attenuates the release of IL-10 in dose-dependent
manner. IL-10 has been shown to contribute in tumor de-
rived immune suppression [39] by suppressing CD4 T cells
[40] and inducing myeloid derived suppressor cells [41].
The increased chemokine secretion suggests that ipili-
mumab can promote not only the cytotoxicity of the ex-
panded ATC but also their ability to recruit endogenous
immune cells [30,31] such as memory T cells, monocytes,
dendritic cells, macrophages, NK cells, and neutrophils.
These data further indicates that ipilimumab can augment
effector activities of ATC while inhibiting the regulatory
components of the immune system (Figure 6).
In summary, we demonstrated that ipilimumab can im-
prove ATC proliferation, enhance the BiAb-mediated
tumor-specific cytotoxicity, and increase cytokine synthe-
sis, while it attenuates Treg activity as shown by decreased
level of IL-10 secretion and reduced Treg population. This
mechanism may be clinically relevant since ipilimumab
treatment of PBMC from GI patients was able to enhance
BiAb-mediated cytotoxicity of ATC directed at pancreatic
cancer cell line COLO356/FG. The approach of using ipi-
limumab to optimize effector functions of ex vivo ex-
panded ATC may improve the efficacy of BiAb-mediated
antigen targeted adoptive T cell immunotherapy without
increasing ipilimumab related toxicities.
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